Cargando…
Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice
The use of rapamycin to extend lifespan and delay age-related disease in mice is well-established despite its potential to impair glucose metabolism which is driven partially due to increased hepatic gluconeogenesis. We tested whether a combination therapeutic approach using rapamycin and metformin...
Autores principales: | Weiss, Roxanne, Fernandez, Elizabeth, Liu, Yuhong, Strong, Randy, Salmon, Adam B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892694/ https://www.ncbi.nlm.nih.gov/pubmed/29579736 http://dx.doi.org/10.18632/aging.101401 |
Ejemplares similares
-
Fasting and rapamycin: diabetes versus benevolent glucose intolerance
por: Blagosklonny, Mikhail V.
Publicado: (2019) -
Rapamycin-induced metabolic defects are reversible in both lean and obese mice
por: Liu, Yuhong, et al.
Publicado: (2014) -
Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity
por: Yang, Shi-Bing, et al.
Publicado: (2011) -
Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus)
por: Ross, Corinna, et al.
Publicado: (2015) -
Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
por: Houde, Vanessa P., et al.
Publicado: (2010)